---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098994"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:50:56.909362+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma doses first subject in Phase 2 COVID study of ratutrelvir; top-line data by year-end 2025

## Summary
- First subject dosed in Phase 2 study of ratutrelvir, a ritonavir-free anti-viral for newly diagnosed COVID.
- Two trials: non-inferiority versus PAXLOVID and a single-arm study for PAXLOVID-ineligible patients.
- Top-line results from both Phase 2 studies expected by year-end 2025.
- Ratutrelvir is once-daily, single tablet for 10 days; aims to reduce rebound and Long COVID risk.

## SEC filing metadata
- accession: 0001104659-25-098994
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/0001104659-25-098994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925098994/tm2528641d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098994
- JSON: https://secwatch.observer/filing/0001104659-25-098994.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.